Mycoplasma: a new potential vector for gene therapy?
The introduction of foreign genetic material in living cells is the basis of the current protocols of gene therapy. The concept that the de novo synthesis of a foreign therapeutic protein requires the entrance of the corresponding gene into target cells via virus or synthetic vectors is directly inherited from experiments on bacterial transduction or transformation. However, the difficulties inherent in the penetration and the expression of foreign DNA into eucaryotic cells are probably responsible for the low efficiency of this therapeutic approach. In this paper, we explore the possibility of avoiding these limiting critical steps by expressing the foreign gene on the surface rather than inside the target cells by the use of mycoplasma, the smallest reported living cell. The absence of transfer of genetic information between this vector and eucaryotic target cells, the sensibility of mycoplasmas to antibiotics and their cytadherance are among the interesting features of this potential vector. The interest of this new vector in the case, e.g. of the gene-directed enzyme prodrug therapy of solid tumors, is discussed.
Berger
F
F
INSERM U318, Neurobiologie Préclinique, CHU Michallon, Grenoble, France.
Canova
C
C
Vicat
J M
JM
Benabid
A L
AL
Wion
D
D
D015316:Genetic Therapy; D005822:Genetic Vectors; D008957:Models, Genetic; D009174:Mycoplasma